---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-23-000045"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T09:25:34.169365+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific beats Q3 estimates; raises FY 2023 adjusted EPS guidance to $1.99-2.02

## Summary
- Q3 net sales $3.527B (+11.2% reported, +10.2% organic); beat guidance of 8.5-10.5% reported and 7-9% organic.
- GAAP EPS $0.34 (vs guidance $0.21-0.25); adjusted EPS $0.50 (vs guidance $0.46-0.48), up from $0.43 a year ago.
- Cardiovascular sales $2.185B (+11.6% reported); MedSurg $1.341B (+10.6%); U.S. grew 8.5%, Asia-Pacific 14.8% reported.
- FY 2023 guidance raised: organic sales growth ~11%; GAAP EPS $1.00-1.04; adjusted EPS $1.99-2.02 (prev. $1.94-1.98).
- Announced agreement to acquire Relievant Medsystems (Intracept system) for vertebrogenic pain; terms not disclosed.

## SEC filing metadata
- accession: 0000885725-23-000045
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/0000885725-23-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/bsx-20231026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-23-000045
- JSON: https://secwatch.observer/filing/0000885725-23-000045.json
- Plain text: https://secwatch.observer/filing/0000885725-23-000045.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported third quarter ended September 30, 2023 results: revenue $3.527 billion, net income $505 million or $0.34 per share, EPS $0.50.
  - Period: third quarter ended September 30, 2023
  - Revenue: $3.527 billion
  - Net income: $505 million or $0.34 per share
  - EPS: $0.50
  - Result: reported results
  source text: Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational 1 basis and 10.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted 3 EPS of $0.50 for the period, compared to $0.43 a year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/0000885725-23-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.